MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
DexCom DPO Ratio 2011-2026 | DXCM
Annual DPO Ratio DexCom
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 67.7 | 71.1 | 70.4 | 76 | 83.8 | 75 | 68.6 | 74.9 | 75.3 | 45.9 | 56.1 | 43.6 | 25.6 | 26.7 | 25.3 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 83.8 | 25.3 | 59.1 |
Quarterly DPO Ratio DexCom
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 88.1 | 79.3 | - | 72.2 | 69.7 | 69.4 | - | 66.4 | 75.2 | 82.5 | - | 32.8 | 27.8 | 67.1 | - | 84.4 | 81.5 | 89.3 | - | 92.8 | 88.9 | 81.5 | - | 62.5 | 71.9 | 72.6 | - | 70.2 | 77.5 | 85.1 | - | - | - | - | - | - | - | - | - | 56.8 | 63.7 | 50.1 | - | 41.4 | 47.8 | 37.2 | - | 25.1 | 27.6 | 28.2 | - | 24.2 | 44.4 | 61.1 | - | 25.4 | 13.4 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 92.8 | 13.4 | 60.4 |
DPO Ratio of other stocks in the Diagnostics research industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
120 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Biomerica
BMRA
|
32.4 | $ 2.13 | - | $ 4.89 M |  USA |
|
Akumin
AKU
|
21.3 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
52.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
45.8 | - | - | $ 562 M |  Britain |
 |
Lantheus Holdings
LNTH
|
23.6 | $ 75.5 | -0.31 % | $ 5.1 B | USA |
 |
DermTech
DMTK
|
47.4 | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
112 | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
106 | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
13.3 | $ 455.28 | -0.36 % | $ 13.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
125 | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
17.7 | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
61.4 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
780 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
43.5 | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
8.98 | - | - | $ 10.7 B | USA |
 |
Mettler-Toledo International
MTD
|
53.4 | $ 1 229.6 | -0.87 % | $ 25.3 B |  Schweiz |
 |
Charles River Laboratories International
CRL
|
24.5 | $ 156.54 | -0.92 % | $ 7.76 B | USA |
 |
IQVIA Holdings
IQV
|
126 | $ 165.42 | -0.95 % | $ 28.4 B | USA |
 |
Myriad Genetics
MYGN
|
45.9 | $ 4.6 | -1.29 % | $ 426 M | USA |
 |
Biocept
BIOC
|
56.3 | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
69 | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
149 | $ 1.25 | -14.38 % | $ 6.81 M | USA |
 |
National Research Corporation
NRC
|
10.1 | $ 17.47 | -0.26 % | $ 391 M | USA |
 |
Interpace Biosciences
IDXG
|
34.4 | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
IDEXX Laboratories
IDXX
|
24.9 | $ 569.86 | -1.5 % | $ 45.8 B | USA |
 |
Illumina
ILMN
|
56.3 | $ 122.99 | -0.65 % | $ 19.6 B | USA |
 |
ICON Public Limited Company
ICLR
|
6.52 | $ 100.22 | -0.13 % | $ 8.27 B |  Irlanda |
 |
Guardant Health
GH
|
48.6 | $ 84.35 | -0.65 % | $ 10.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
50 | - | - | $ 10.6 B |  Niderland |
 |
Pacific Biosciences of California
PACB
|
59.7 | $ 1.38 | -1.08 % | $ 414 M | USA |
 |
Precipio
PRPO
|
53 | $ 26.93 | - | $ 35 M | USA |
 |
Personalis
PSNL
|
67.3 | $ 7.71 | 1.37 % | $ 457 M | USA |
 |
Chembio Diagnostics
CEMI
|
52.5 | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
31.5 | $ 263.52 | -0.36 % | $ 21.9 B | USA |
 |
Motus GI Holdings
MOTS
|
1.72 | - | -34.28 % | $ 263 K |  Israel |
 |
RadNet
RDNT
|
23.5 | $ 60.39 | -2.19 % | $ 4.54 B | USA |
 |
ENDRA Life Sciences
NDRA
|
1.65 K | $ 3.41 | -2.16 % | $ 1.83 M | USA |
 |
NeoGenomics
NEO
|
19.7 | $ 7.91 | -2.35 % | $ 1.01 B | USA |
 |
Agilent Technologies
A
|
50.1 | $ 111.72 | -0.27 % | $ 34 B | USA |
 |
Natera
NTRA
|
17.9 | $ 194.13 | -2.98 % | $ 19.1 B | USA |
 |
CareDx, Inc
CDNA
|
44.2 | $ 17.24 | -1.82 % | $ 919 M | USA |
 |
OPKO Health
OPK
|
43.1 | $ 1.14 | -0.88 % | $ 791 M | USA |
 |
Senseonics Holdings
SENS
|
68 | $ 6.58 | -0.68 % | $ 275 M | USA |
 |
Castle Biosciences
CSTL
|
52 | $ 25.84 | 0.35 % | $ 718 M | USA |
 |
Sotera Health Company
SHC
|
46.9 | $ 13.77 | -0.79 % | $ 3.91 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
14.7 | $ 194.57 | -0.54 % | $ 21.6 B | USA |
 |
DarioHealth Corp.
DRIO
|
112 | $ 7.37 | -1.73 % | $ 29.4 M | Israel |